TRANSKRYPCJA 🔗
WEBVTT
00:00:00.000 --> 00:00:03.759
Could cataract surgery give you a glaucoma drug that lasts for years?
00:00:03.919 --> 00:00:10.720
The Bimatoprost releasing lens explained, potentially, but not for everyone, and not as a cure for glaucoma.
00:00:10.960 --> 00:00:21.679
Spyglass Pharma's investigational Bimatoprost Drug Pad Interocular Lens System, or BIM IOL, combines an artificial cataract lens with two small drug-releasing pads.
00:00:21.839 --> 00:00:26.960
The lens is designed to release Bimatoprost, a pressure-lowering medicine, for about three years.
00:00:27.199 --> 00:00:28.879
The early results are striking.
00:00:29.120 --> 00:00:40.399
In a randomized trial, roughly 96 to 98% of evaluable patients who received the drug-releasing lens were not using additional pressure-lowering drops at 12 months.
00:00:40.640 --> 00:00:48.079
A much smaller first-in-human study found that 20 of 21 participants followed for three years remained drop-free.
00:00:48.320 --> 00:00:51.520
Those results make the idea worth taking seriously.
00:00:51.759 --> 00:01:02.000
But drop-free is not the same as glaucoma-free, and the strongest three-year result comes from a small, uncontrolled study, not the larger randomized trial.
00:01:02.240 --> 00:01:11.040
This article reviews the evidence available as of October 18, 2026, including the latest American Academy of Ophthalmology meeting presentation.
00:01:11.280 --> 00:01:17.359
The BIM IOL remains investigational and not approved by the United States Food and Drug Administration.
00:01:17.680 --> 00:01:20.239
AAO 2026 results coverage.
00:01:20.480 --> 00:01:24.560
What is the spyglass bimatoprost drug pad intraocular lens?
00:01:24.719 --> 00:01:30.640
During cataract surgery, the cloudy natural lens is removed and replaced with an intraocular lens.
00:01:31.359 --> 00:01:41.760
The spyglass system uses a monofocal artificial lens with two bimatoprost containing pads attached near the junction between the lens's clear center and its supporting arms.
00:01:42.000 --> 00:01:47.519
The lens and pads are placed inside the eye's capsular bag where the natural lens used to sit.
00:01:48.239 --> 00:01:54.079
The pads are positioned outside the main visual area and are designed to release bimatoprost slowly.
00:01:54.239 --> 00:02:02.079
Unlike an implant placed in the eye's drainage angle, the BIM IOL is intended to leave that angle available for future glaucoma procedures.
00:02:02.239 --> 00:02:09.439
Adding the pads requires preparation of the lens but is intended to fit within a routine cataract surgery workflow.
00:02:09.680 --> 00:02:11.759
Publish three-year pilot study.
00:02:12.240 --> 00:02:15.840
The system is designed to deliver medication for three years.
00:02:16.080 --> 00:02:27.120
That is a design goal supported by laboratory release testing and early human pressure measurements, not yet proof that every patient will receive three full years of effective treatment.
00:02:27.360 --> 00:02:31.120
Load full transcript
What did the AAO 2026 presentation report?
00:02:31.439 --> 00:02:45.039
At the American Academy of Ophthalmology annual meeting in New Orleans, held October 9-12, 2026, investigator Fia Zaman presented 12-month results from Spyglass's randomized phase one-half trial.
00:02:45.280 --> 00:02:52.639
The trial enrolled people with a cataract and either mild to moderate open-angle glaucoma or ocular hypertension.
00:02:52.960 --> 00:02:58.080
AAO 2026 presentation coverage, trial groups and pressure results.
00:02:58.240 --> 00:03:00.960
A total of 104 people were randomized.
00:03:01.120 --> 00:03:05.280
For the full table, please open this article on visualfieldtest.com.
00:03:05.520 --> 00:03:12.159
All participants stopped their existing pressure lowering treatment for a washout period before the baseline measurements.
00:03:12.400 --> 00:03:18.319
The exact group mean washout pressures were not included in the public AAO report I could verify.
00:03:18.879 --> 00:03:29.199
Dividing the reported pressure reductions by the rounded percentages gives an approximate baseline of about 25 to 27 mmHAS, depending on group and measurement time.
00:03:29.599 --> 00:03:34.000
These are calculated estimates, not separately published baseline figures.
00:03:34.319 --> 00:03:41.439
AAO 2026 results report the lower dose group had a numerically larger reduction than the higher dose group.
00:03:41.599 --> 00:03:45.280
That does not establish that 39 micrograms is better.
00:03:45.520 --> 00:03:53.599
These reported averages do not demonstrate a clear dose response relationship, and the small groups are not a definitive dose comparison.
00:03:54.000 --> 00:03:57.039
How many patients were off pressure lowering drops?
00:03:57.280 --> 00:04:06.560
At 12 months, the presentation reported that 98% of patients in the 78 microgram group were off additional pressure lowering medication.
00:04:06.800 --> 00:04:12.639
96% of patients in the 39 microgram group were off additional pressure lowering medication.
00:04:12.960 --> 00:04:17.519
Control group participants were not reported as drop-free in the same sense.
00:04:17.759 --> 00:04:21.360
They were still using their assigned twice-daily timelol.
00:04:21.519 --> 00:04:30.240
The company has summarized the combined treated groups as approximately 97% off-topical pressure lowering therapy at 12 months.
00:04:30.560 --> 00:04:34.800
Medication-free here means free of additional pressure-lowering eye drops.
00:04:35.040 --> 00:04:42.079
Patients in the BIM IOL groups used artificial tears as part of the trial and still received ordinary postoperative eye care.
00:04:42.480 --> 00:04:46.560
AAO 2026 report and spyglass phase one results.
00:04:46.800 --> 00:04:49.680
Vision, corneal cells, and adverse events.
00:04:49.920 --> 00:04:52.480
The reported visual outcomes were reassuring.
00:04:52.639 --> 00:04:58.800
All evaluable eyes in all three groups achieved best corrected distance vision of 2032 or better.
00:04:59.199 --> 00:05:10.480
Vision of 2020 or better was reported in 74% of the 78 microgram group, 65% of the 39 microgram group, and 63% of the control group.
00:05:10.639 --> 00:05:16.639
Average vision across groups was about 86 letters, roughly equivalent to 2020 vision.
00:05:16.879 --> 00:05:24.800
The presentation also reported corneal endothelial cell density, a measure of the health of the cells lining the inside of the cornea.
00:05:25.120 --> 00:05:29.439
For the full table, please open this article on visualfieldtest.com.
00:05:29.680 --> 00:05:38.000
The investigators characterize the overall safety profile and endothelial cell loss as comparable to routine cataract surgery.
00:05:38.240 --> 00:05:44.879
However, the numerically larger decline in the smaller 39 microgram group deserves follow-up.
00:05:45.439 --> 00:05:48.399
These are calculations from reported group averages.
00:05:48.639 --> 00:05:55.279
The public conference coverage does not provide a full adjusted comparison or enough detail to interpret the differences confidently.
00:05:55.439 --> 00:05:58.480
AAO 2026 Safety and Vision Results.
00:05:58.720 --> 00:06:10.240
Any adverse event was reported in 21 people in the 78 microgram group, 41%, 10 in the 39 microgram group, 43%, and 11 in the control group, 37%.
00:06:11.040 --> 00:06:18.879
The report described no serious adverse events, secondary surgical interventions, or lens explantations through 12 months.
00:06:19.120 --> 00:06:28.560
The public report does not provide a complete event-by-event breakdown, so the overall percentages should not be read as the proportion who had a problem caused by the drug pads.
00:06:30.319 --> 00:06:34.240
How meaningful is a 96 to 98% drop-free result?
00:06:34.800 --> 00:06:36.879
It is a meaningful early signal.
00:06:37.120 --> 00:06:45.519
If confirmed in larger and longer studies, avoiding daily pressure-lowering drops could reduce the burden of remembering, handling, and paying for them.
00:06:45.680 --> 00:06:49.199
That could matter especially for people who struggle with daily dosing.
00:06:49.439 --> 00:06:51.279
But the headline needs context.
00:06:51.439 --> 00:06:56.319
It does not mean 98% of patients stopped drops they were taking nowhere.
00:06:56.720 --> 00:07:02.399
About one-third of trial participants were taking no pressure-lowering medication at screening.
00:07:02.560 --> 00:07:10.160
They may have had elevated pressure without current treatment, or they may have been suitable for observation under their clinician's care.
00:07:10.319 --> 00:07:20.480
So the reported drop-free percentage is not the same as saying that 96 to 98% of people who had been using drops successfully stopped them after surgery.
00:07:20.720 --> 00:07:24.480
The report does not provide enough detail to calculate that specific number.
00:07:24.720 --> 00:07:27.519
AAO 2026 study details.
00:07:28.800 --> 00:07:32.000
The control group also had a large pressure reduction.
00:07:32.319 --> 00:07:37.920
The control group had ordinary cataract surgery, received a standard lens, and used timolol.
00:07:38.000 --> 00:07:44.319
Its reported pressure reduction, about 35% at 12 months, was close to the reductions in the drug pad groups.
00:07:44.399 --> 00:07:52.160
This trial therefore supports the idea that the BIM IOL can maintain pressure control while avoiding assigned TMALOL drops.
00:07:52.319 --> 00:07:57.439
It does not show that the BIM IOL lowered pressure more than the control treatment.
00:07:57.759 --> 00:08:03.120
Cataract surgery itself can lower pressure, especially when the starting pressure is high.
00:08:03.360 --> 00:08:10.319
Estimates differ depending on the patients studied and whether pressure-lowering medications were stopped before measurement.
00:08:10.720 --> 00:08:22.399
A 2024 review of cataract surgery trials found a 12-month average reduction of about 3.8 millimeter grams overall, with a larger average reduction in studies that used a medication washout.
00:08:22.639 --> 00:08:25.120
Cataract surgery meta-analysis.
00:08:25.439 --> 00:08:28.800
Drop-free is not the same as glaucoma controlled for life.
00:08:28.879 --> 00:08:34.240
The phase one-half trial reported eye pressure, vision, medication use, and safety.
00:08:34.399 --> 00:08:42.639
It did not establish that the lens prevents future visual field loss, stops optic nerve damage, or removes the need for future glaucoma care.
00:08:43.039 --> 00:08:48.159
The 12-month results are also interim data presented at a medical meeting.
00:08:48.320 --> 00:08:53.360
The available report is not a full peer-reviewed paper with all trial details.
00:08:53.600 --> 00:09:02.960
Bottom line, the result is promising evidence of a strong chance of being free from additional pressure-lowering drops at one year in this selected study group.
00:09:03.360 --> 00:09:09.759
It is not yet proof that most people having cataract surgery can avoid glaucoma treatment indefinitely.
00:09:10.000 --> 00:09:14.000
Does the pressure lowering effect really last three years?
00:09:14.320 --> 00:09:21.120
The most direct human evidence comes from a small, prospective, non-randomized first-in-human study in Honduras.
00:09:21.279 --> 00:09:24.159
The published paper says 24 people consented.
00:09:24.320 --> 00:09:28.559
Company materials have described 23 people assigned to dose groups.
00:09:28.799 --> 00:09:31.360
21 were followed through 36 months.
00:09:31.519 --> 00:09:42.720
The study tested older configurations containing 75, 150, or 300 micrograms of bimatoprost, not the 39 and 78 microgram doses in the later randomized trial.
00:09:42.960 --> 00:09:46.639
Published three-year pilot study and company 36-month results.
00:09:46.879 --> 00:09:59.519
At 36 months, the reported average pressure for evaluable participants had fallen from 25.12.5 mmhergrams after washout to 15.9-2.7 mm, a reduction of about 37%.
00:10:00.639 --> 00:10:06.000
20 of 21 participants were still free of topical pressure lowering medication.
00:10:06.240 --> 00:10:15.840
All 21 had at least a 20% pressure reduction from baseline, and 19 of 21 had pressure below 18 mmHH drams at their final visit.
00:10:16.000 --> 00:10:21.919
One participant in the highest dose group restarted a pressure lowering medication at month 30.
00:10:22.159 --> 00:10:27.440
The researchers reported that pressure lowering was broadly maintained through three years.
00:10:28.000 --> 00:10:36.799
There was a small pressure uptick in the 150 microgram group during year three, but not a similar pattern in the 75 microgram group.
00:10:37.039 --> 00:10:44.240
The paper's authors suggested that the increase could reflect the variability of small groups rather than waning drug effect.
00:10:44.399 --> 00:10:46.799
The study cannot settle that question.
00:10:47.120 --> 00:10:48.320
Three-year study.
00:10:48.559 --> 00:10:53.919
This supports three-year clinical pressure control in a very small selected group.
00:10:54.080 --> 00:10:59.279
It does not prove that drug release itself remained perfectly constant inside each eye.
00:10:59.519 --> 00:11:06.240
No published patient-level drug release measurement shows exactly how much medicine was being released over time.
00:11:06.559 --> 00:11:16.639
Laboratory testing is reported to show sustained release for more than three years, while the human study offers an indirect clinical measure, eye pressure.
00:11:16.879 --> 00:11:24.960
The first inhuman study also selected participants who had previously responded to prostaglandin medicines, such as bimataprost.
00:11:25.519 --> 00:11:31.759
It had no cataract surgery-only control group, no randomization, and no masking.
00:11:32.159 --> 00:11:42.240
The authors themselves noted that cataract surgery can lower pressure and that the study was not designed to establish how the system would perform in more difficult-to-control glaucoma.
00:11:42.639 --> 00:11:49.759
Spyglass said in August 2026 that four-year follow-up results were expected in the fourth quarter of 2026.
00:11:50.000 --> 00:11:54.240
Those results were not yet available by October 18, 2026.
00:11:55.039 --> 00:11:58.399
Spyglass second quarter 2026 update.
00:11:58.720 --> 00:12:01.039
What happens when the drug runs out?
00:12:01.279 --> 00:12:04.480
The drug pads are designed to be non-bioerotable.
00:12:04.639 --> 00:12:06.960
They do not dissolve as the medicine is released.
00:12:07.120 --> 00:12:12.879
Once their medication is depleted, the pads are intended to remain attached to the lens inside the capsular bag.
00:12:13.120 --> 00:12:14.879
Spyglass Company filing.
00:12:15.039 --> 00:12:16.399
Can the pads be replaced?
00:12:16.559 --> 00:12:21.120
There is no established procedure to replace just the pads inside the eye.
00:12:21.279 --> 00:12:23.039
They are attached to the lens.
00:12:23.279 --> 00:12:25.919
Can other glaucoma treatment be added?
00:12:26.159 --> 00:12:33.440
In principle,
a clinician could consider pressure lowering drops, laser treatment, or surgery if pressure rises.
00:12:33.679 --> 00:12:43.519
Using another sustained release implant after BIM IOL has not been established in clinical studies, and the choice would depend on the person's eye and the other product's instructions.
00:12:43.679 --> 00:12:45.759
Can conventional drops be restarted?
00:12:45.919 --> 00:12:46.320
Yes.
00:12:46.559 --> 00:12:52.399
A lens that has stopped releasing enough medicine does not prevent a doctor from prescribing drops again.
00:12:52.720 --> 00:12:56.159
Can selective laser treatment or glaucoma surgery still be done?
00:12:56.399 --> 00:13:00.159
The pads sit in the capsular bag rather than the drainage angle.
00:13:00.320 --> 00:13:03.600
That is intended to preserve the angle for future treatment.
00:13:03.759 --> 00:13:11.840
However, there are not yet large clinical series testing every possible sequence of BIM IOL followed by a glaucoma procedure.
00:13:12.480 --> 00:13:16.000
Would the whole lens need replacing when the pads are empty?
00:13:16.240 --> 00:13:18.799
Not as a planned part of routine treatment.
00:13:19.039 --> 00:13:26.320
Replacing an artificial lens is a separate operation with its own risks, not a standard way to reload the BIM IOL.
00:13:26.480 --> 00:13:31.840
The lens would generally stay in place unless there were another clinical reason to exchange it.
00:13:32.240 --> 00:13:41.840
Spyglass is also developing a separate Bimataprost drug ring system, designed to be removable and replaceable for people who already have an artificial lens.
00:13:42.080 --> 00:13:43.840
It remains investigational.
00:13:44.000 --> 00:13:48.639
It is not an approved or proven way to retreat patients whose BIM IL pads have run out.
00:13:48.879 --> 00:13:50.879
Spyglass Company filing.
00:13:51.120 --> 00:13:54.559
How does BIM IL compare with other glaucoma treatments?
00:13:54.799 --> 00:13:58.480
These figures come from different trials and different patient groups.
00:13:58.639 --> 00:14:04.799
Except for the BIM IOL trials comparison with TMALOL, they are not head-to-head comparisons.
00:14:05.200 --> 00:14:10.960
Starting pressure, medication washout, disease severity, and follow-up time all affect the results.
00:14:11.120 --> 00:14:15.360
For the full table, please open this article on VisualFieldTest.com.
00:14:15.759 --> 00:14:29.440
Sources: First Line Glaucoma Medicine Review, IDOSE TR United States Label, Derista United States Label, Light Six Year Results, American Academy of Ophthalmology Cataractin Glaucoma Guidance, and Five-Year Hydrus Trial.
00:14:29.679 --> 00:14:31.600
The comparison makes an important point.
00:14:31.759 --> 00:14:38.320
The roughly 35% pressure reduction in the BIM IOL trial does not establish superiority over ordinary treatment.
00:14:38.639 --> 00:14:50.799
Its clearest potential advantage is that many participants did not need additional pressure lowering drops while achieving pressure reductions similar to the Timolol plus cataract surgery control group.
00:14:51.759 --> 00:14:55.039
Does a permanent drug pad create long-term risks?
00:14:55.279 --> 00:15:07.679
So far, the small human studies have not revealed a clear mechanical or vision problem, but three years in a small group is not the same as proving lifetime safety for a device that may remain in an eye for decades.
00:15:08.000 --> 00:15:09.919
Corneal endothelial cells.
00:15:10.159 --> 00:15:18.720
In the randomized study, the reported 12-month endothelial cell results were described as comparable overall to routine cataract surgery.
00:15:18.879 --> 00:15:24.639
In the three-year pilot, cell density was measured at 6 and 12 months, not at 36 months.
00:15:24.799 --> 00:15:29.360
The authors also noted that the counts were not confirmed by a formal reading center.
00:15:29.519 --> 00:15:34.559
This leaves a significant gap in the evidence about long-term corneal cell health.
00:15:35.120 --> 00:15:38.639
Inflammation, scarring, and drug crystallization.
00:15:38.879 --> 00:15:46.559
The first in-human study reported unremarkable postoperative inflammation and no serious implant-related adverse events.
00:15:46.720 --> 00:15:52.639
It did not report drug crystallization, but the small study was not large enough to rule out rare events.
00:15:52.879 --> 00:16:02.240
Long-term scarring or fibrosis around the pads has not been established as a clinical problem, but it also has not been adequately ruled out over a patient's lifetime.
00:16:03.120 --> 00:16:10.480
Bermatoprost belongs to a class of medicines that can be associated with inflammation or macular swelling in some settings.
00:16:11.600 --> 00:16:26.159
No such serious implant-related signal was reported in the small spyglass studies, but established warnings for bimatoprost-containing treatments are a reason to continue monitoring rather than assume that a sustained release version has no class-related risk.
00:16:26.399 --> 00:16:28.480
Darista United States label.
00:16:28.960 --> 00:16:31.440
Lens stability and visual quality.
00:16:31.679 --> 00:16:38.559
In the three-year pilot, the researchers reported no lens dislocations, pad displacements, or explantations.
00:16:38.799 --> 00:16:43.759
All study eyes had best corrected vision of 2030 or better at final follow-up.
00:16:44.080 --> 00:16:52.559
The study reported no clinically significant posterior capsule opacification, a clouding that can sometimes develop behind an artificial lens.
00:16:52.799 --> 00:16:55.679
Those findings are reassuring but preliminary.
00:16:55.840 --> 00:17:05.839
They do not answer every question about lens optics, uncommon mechanical problems, or what happens after procedures such as laser treatment for posterior capsule clouding.
00:17:06.079 --> 00:17:09.279
The early clinical work used a monofocal lens.
00:17:09.519 --> 00:17:16.240
Claims that the pad system may work with other lens designs are not
the same as clinical evidence for those designs.
00:17:16.559 --> 00:17:19.039
Future retinal or glaucoma surgery.
00:17:19.279 --> 00:17:28.000
Because the BIM IOL is placed in the capsular bag and not in the eye's drainage angle, it is not intended to block the angle used for many glaucoma treatments.
00:17:28.240 --> 00:17:34.240
That makes future laser treatment, angle surgery, or other glaucoma surgery anatomically plausible.
00:17:34.480 --> 00:17:39.279
But the claim that it preserves options is based mainly on where the lens sits.
00:17:39.519 --> 00:17:44.079
Dedicated studies of later procedures in BIM IOL eyes are still needed.
00:17:44.240 --> 00:17:49.839
The early studies likewise do not establish how the pads affect every future retinal operation.
00:17:50.079 --> 00:18:03.920
Their location outside the main visual axis and inside the capsular bag suggests that they should not automatically prevent retinal surgery, but there is not yet a large body of clinical experience to confirm all possible surgical scenarios.
00:18:04.240 --> 00:18:09.519
Spyglass BIM IOL versus IDOSTR, which is the better long-term idea?
00:18:09.680 --> 00:18:11.039
They solve different problems.
00:18:11.279 --> 00:18:17.519
BIM IOL is designed to make the cataract operation itself carry several years of medication delivery.
00:18:17.680 --> 00:18:23.359
It avoids a separate drainage angle implant procedure and is intended to leave the angle available.
00:18:23.519 --> 00:18:28.960
The trade-off is that the pads cannot be exchanged independently of the artificial lens.
00:18:29.440 --> 00:18:33.279
IDOSTR is a separate implant placed in the drainage angle.
00:18:33.440 --> 00:18:43.680
Its January 2026 United States label includes a method to remove the old implant after placing a new one, subject to corneal cell assessment and other precautions.
00:18:43.839 --> 00:18:47.119
Readministration is not recommended more than once per year.
00:18:47.359 --> 00:18:55.039
That makes it more adjustable and retreatable in principle, but retreatment involves another procedure and removal of the prior implant.
00:18:55.440 --> 00:18:57.839
IDOS TR United States label.
00:18:58.079 --> 00:19:02.400
For the full table, please open this article on VisualFieldTest.com.
00:19:02.799 --> 00:19:04.960
Which is the better long-term idea?
00:19:05.200 --> 00:19:15.200
For someone already having cataract surgery who wants to avoid a separate glaucoma procedure, the BIM IOL concept is attractive, if its longer-term safety and effectiveness are confirmed.
00:19:15.359 --> 00:19:28.319
For a person who values the ability to replace or repeat the drug source, IDOSTR has the more flexible design, though it requires angle surgery and has its own placement, removal, and endothelial cell considerations.
00:19:28.799 --> 00:19:32.720
There is no head-to-head trial establishing one as better overall.
00:19:33.039 --> 00:19:43.519
Spyglass says a dedicated add-on billing code was approved
in 2026 and anticipates a physician-administered drug reimbursement pathway if the product is approved.
00:19:43.759 --> 00:19:49.279
Those are company expectations, not a final guarantee of coverage or a known patient price.
00:19:49.519 --> 00:19:54.319
The company has not published a BIM IOL price or cost effectiveness analysis.
00:19:54.559 --> 00:19:58.799
Spyglass second quarter 2026 update and company filing.
00:19:59.039 --> 00:20:02.960
What is happening in phase 3 and when could it reach patients?
00:20:03.200 --> 00:20:10.240
SpyGlass is running two registrational phase 3 trials, SGP 005 and SGP006.
00:20:10.480 --> 00:20:13.920
The trials are designed to enroll about 400 participants each.
00:20:14.000 --> 00:20:19.680
They compare the 78 microgram BIM IOL with a standard lens plus twice daily time al.
00:20:20.480 --> 00:20:28.400
The co-primary outcomes include pressure change and the proportion of patients achieving best corrected distance vision of 2040 or better.
00:20:28.640 --> 00:20:32.960
Participants are expected to be followed for up to 36 months.
00:20:33.279 --> 00:20:35.359
Phase 3 trial announcement.
00:20:35.599 --> 00:20:42.319
Spyglass reported in August 2026 that enrollment remained on track for completion in 2027.
00:20:42.720 --> 00:20:52.319
The company has said it plans to submit a new drug application to the United States Food and Drug Administration in 2028 if the Phase 3 results support it.
00:20:52.640 --> 00:20:58.480
A possible approval in 2029 or later is therefore conceivable, but not promised.
00:20:58.640 --> 00:21:06.960
Recruitment delays, trial results, the regulator's review, or a request for additional durability or safety evidence could shift the timeline.
00:21:07.200 --> 00:21:13.519
Spyglass August 2026 update and company filing, a cautious estimate of the chances.
00:21:13.759 --> 00:21:18.240
The following are judgment estimates, not published statistical forecasts.
00:21:18.640 --> 00:21:24.720
Chance both phase three trials meet their short-term primary endpoints, roughly 65 to 75%.
00:21:25.519 --> 00:21:35.759
The randomized phase one half pressure results and vision data are encouraging, but the pivotal trials must reproduce them in a larger population, and both trials must meet their targets.
00:21:36.000 --> 00:21:41.200
Chance of eventual United States approval from the current stage, roughly 50 to 60%.
00:21:41.839 --> 00:21:44.960
Approval depends on more than a short-term pressure result.
00:21:45.279 --> 00:21:52.640
The regulator will also assess the combined drug and lens product, safety, vision, manufacturing, and the adequacy of follow-up.
00:21:53.039 --> 00:22:01.359
Likely medication-free share at three years in patients similar to the study population, a cautious estimate is about 75 to 90%.
00:22:02.000 --> 00:22:12.960
The small first-in-human study reported 20 of 21 off drops at three years, but that result has not yet been reproduced at scale with the intended 78 microgram dose.
00:22:13.359 --> 00:22:24.640
Likely share needing additional pressure-lowering treatment by three years, perhaps 10 to 25%, depending on disease severity and how strict a person's pressure target is.
00:22:24.880 --> 00:22:30.079
This estimate is uncertain and includes people who may need drops or another procedure.
00:22:30.240 --> 00:22:33.039
The last two estimates are not trial findings.
00:22:33.200 --> 00:22:40.240
They extrapolate from small, selected studies and should not be used to predict an individual patient's outcome.
00:22:40.559 --> 00:22:42.799
Which patients might benefit most?
00:22:43.039 --> 00:23:05.839
If later studies support the early results, the most plausible candidates would be people who need cataract surgery anyway, have ocular hypertension, or mild to moderate open-angle glaucoma, have a pressure target that can reasonably be met with one pressure-lowering medicine, have previously responded to prostaglandin treatment, want to reduce the burden of daily glaucoma drops.
00:23:06.079 --> 00:23:16.640
The early evidence does not establish BIM IOL as a standalone answer for advanced glaucoma, rapid disease progression, or people who need very low pressure targets.
00:23:16.799 --> 00:23:19.599
Those patients may need more intensive treatment.
00:23:19.839 --> 00:23:29.359
The three-year pilot also selected people who had responded to prostaglandin medicines, which limits how well its results may apply to people who do not respond.
00:23:30.240 --> 00:23:35.599
Could cataract surgery become a one-time treatment for both cataract and glaucoma?
00:23:35.759 --> 00:23:41.680
It could become a one-time cataract procedure that provides years of pressure-lowering medicine for some people.
00:23:41.920 --> 00:23:44.079
It is not a one-time cure for glaucoma.
00:23:44.400 --> 00:23:51.519
The strongest early promise is freedom from daily pressure-lowering drops, not freedom from glaucoma treatment or follow-up.
00:23:52.319 --> 00:23:54.240
The drug supply is finite.
00:23:54.400 --> 00:24:03.440
Some people may need drops or another procedure before or after it runs out, and pressure control does not reverse existing optic nerve damage.
00:24:03.680 --> 00:24:09.920
People with glaucoma still need ongoing checks of eye pressure, optic nerve health, and vision.
00:24:10.079 --> 00:24:21.599
The BIM IOL could eventually make treatment easier for a subset of people who are already having cataract surgery, but it cannot yet be considered a replacement for long-term glaucoma monitoring.
00:24:21.839 --> 00:24:25.599
American Academy of Ophthalmology Guidance on Open Angle Glaucoma.
00:24:26.000 --> 00:24:29.920
All links to sources are available in the text version of this article.
00:24:30.160 --> 00:24:33.759
You can find the full article at VisualFieldtest.com.
00:24:34.319 --> 00:24:35.519
Thanks for listening.
00:24:35.680 --> 00:24:41.599
To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.